KALAMAZOO, Mich.--(BUSINESS WIRE)--ADMETRx, a CRO (contract research organization) committed to providing the best in vitro ADME discovery support possible, is pleased to announce a strategic partnership with CeeTox, a CRO committed to the same high standards of performance using in vitro models to predict toxicity. The logical integration of toxicity screening and ADME testing in drug discovery lead selection and optimization, particularly in the assessment of potential drug-drug interactions and idiosyncratic toxicities, means the ADMETRx-CeeTox alliance will provide the pharmaceutical and biotech industry with maximum efficiencies to improve effectiveness in discovery decision-making.
